Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 209

1.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
2.

Cancer Prevention: Lessons Learned and Future Directions.

Dunn BK, Kramer BS.

Trends Cancer. 2016 Dec;2(12):713-722. doi: 10.1016/j.trecan.2016.11.003.

PMID:
28138568
3.

Breast-Cancer Tumor Size and Screening Effectiveness.

Welch HG, Prorok PC, Kramer BS.

N Engl J Med. 2017 Jan 5;376(1):94-5. doi: 10.1056/NEJMc1614282. No abstract available.

4.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM.

Cancer Prev Res (Phila). 2017 Feb;10(2):99-107. doi: 10.1158/1940-6207.CAPR-16-0230. Epub 2016 Dec 13. Review.

PMID:
27965286
5.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

PMID:
27911486
6.

The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications.

Doroudi M, Kramer BS, Pinsky PF.

J Med Screen. 2016 Nov 30. pii: 0969141316680381. [Epub ahead of print]

PMID:
27903809
7.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

PMID:
27615399
8.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

Welch HG, Prorok PC, O'Malley AJ, Kramer BS.

N Engl J Med. 2016 Oct 13;375(15):1438-1447.

9.

Population-based screening for cancer: hope and hype.

Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.

Nat Rev Clin Oncol. 2016 Sep;13(9):550-65. doi: 10.1038/nrclinonc.2016.50. Epub 2016 Apr 13. Review.

PMID:
27071351
10.

Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

Patz EF Jr, Greco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR.

Lancet Oncol. 2016 May;17(5):590-9. doi: 10.1016/S1470-2045(15)00621-X. Epub 2016 Mar 18.

11.

Reply to J. Cabezas et al.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2016 Jan 20;34(3):290-1. doi: 10.1200/JCO.2015.64.3064. Epub 2015 Dec 7. No abstract available.

PMID:
26644541
12.

Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.

Srivastava S, Reid BJ, Ghosh S, Kramer BS.

J Cell Physiol. 2016 Sep;231(9):1870-5. doi: 10.1002/jcp.25227. Epub 2016 Apr 29. Review.

PMID:
26505642
13.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Pinsky PF, Kramer BS.

J Natl Cancer Inst. 2015 Oct 19;107(11). pii: djv226. doi: 10.1093/jnci/djv226. Print 2015 Nov.

14.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK, Steele VE, Fagerstrom RM, Topp CF, Ransohoff D, Cunningham C, Lubet R, Ford LG, Kramer BS.

J Natl Cancer Inst. 2015 Sep 28;107(12):djv259. doi: 10.1093/jnci/djv259. Print 2015 Dec.

15.

Study designs for determining and comparing sensitivities of disease screening tests.

Prorok PC, Kramer BS, Miller AB.

J Med Screen. 2015 Dec;22(4):213-20. doi: 10.1177/0969141315600003. Epub 2015 Sep 22.

PMID:
26396138
16.

Latent class instrumental variables: a clinical and biostatistical perspective.

Baker SG, Kramer BS, Lindeman KS.

Stat Med. 2016 Jan 15;35(1):147-60. doi: 10.1002/sim.6612. Epub 2015 Aug 4.

17.

Comprehensive Quality Management (CQM) in the PLCO Trial.

Gohagan JK, O'Brien B, Hasson MA, Umbel KD, Bridgeman B, Kramer BS, Reding D, Gren L, Wright P, Riley T, Prorok PC.

Rev Recent Clin Trials. 2015;10(3):223-32.

PMID:
26238118
18.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

Gohagan JK, Prorok PC, Greenwald P, Kramer BS.

Rev Recent Clin Trials. 2015;10(3):173-80. Review.

PMID:
26238115
19.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

Kent EE, Mitchell SA, Castro KM, DeWalt DA, Kaluzny AD, Hautala JA, Grad O, Ballard RM, McCaskill-Stevens WJ, Kramer BS, Clauser SB.

J Clin Oncol. 2015 Aug 20;33(24):2705-11. doi: 10.1200/JCO.2014.60.6210. Epub 2015 Jul 20.

20.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

Baker SG, Kramer BS.

J Clin Oncol. 2015 Aug 10;33(23):2578-80. doi: 10.1200/JCO.2014.58.0092. Epub 2015 Jun 29. No abstract available.

Supplemental Content

Loading ...
Support Center